
    
      Patients diagnosed with AML, younger than 61 year of age assigned for intensive chemotherapy,
      and diagnosed with standard or intermediate risk AML, will undergo BM examination on the
      fifth day of induction. Patients in whom BM blast count at the fifth day of induction will be
      lower than 5% will proceed therapy with consolidations or autologous SCT with-holding the
      option for allo-SCT. MRD monitoring will apply to those with reliable molecular marker.
    
  